Literature DB >> 15589005

Comparison of response to cardiac resynchronization therapy in patients with sinus rhythm versus chronic atrial fibrillation.

Sander G Molhoek1, Jeroen J Bax, Gabe B Bleeker, Eric Boersma, L van Erven, Paul Steendijk, Ernst E van der Wall, Martin J Schalij.   

Abstract

Cardiac resynchronization therapy (CRT) is a new therapeutic option for patients who have drug-refractory end-stage heart failure. Much information has been obtained from patients who have sinus rhythm, but the use of CRT in patients who have chronic atrial fibrillation (AF) has not been studied extensively. Accordingly, we evaluated the clinical response and long-term survival rate of CRT in patients who had heart failure and chronic AF, and the results were compared with those in patients who had sinus rhythm and who underwent CRT. Sixty patients who had end-stage heart failure (30 had sinus rhythm and 30 had chronic AF), New York Heart Association classes III to IV, left ventricular ejection fraction <35%, QRS interval >120 ms, and a left bundle branch block received a biventricular pacemaker. New York Heart Association class, Minnesota Quality of Life score, and 6-minute walking distance were evaluated at baseline and after 6 months of CRT. Long-term follow-up was </=2 years. New York Heart Association class, Minnesota Quality of Life score, and 6-minute walking distance improved significantly in the 2 groups after 6 months of CRT. The number of nonresponders was greater among patients who had AF. Nevertheless, the long-term survival rate was comparable between patients who had sinus rhythm and those who had AF. Patients who had AF demonstrated comparable benefit from CRT as those who had sinus rhythm.

Entities:  

Mesh:

Year:  2004        PMID: 15589005     DOI: 10.1016/j.amjcard.2004.08.028

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  58 in total

1.  Cardiac resynchronisation therapy in chronic atrial fibrillation: impact on left atrial size and reversal to sinus rhythm.

Authors:  P Kiès; C Leclercq; G B Bleeker; C Crocq; S G Molhoek; C Poulain; L van Erven; M Bootsma; K Zeppenfeld; E E van der Wall; J-C Daubert; M J Schalij; J J Bax
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

Review 2.  Role of resynchronisation therapy and implantable cardioverter defibrillators in heart failure.

Authors:  S Ellery; L Williams; M Frenneaux
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

3.  Cardiac resynchronization therapy: the MGH experience.

Authors:  Jagmeet P Singh; Jeremy N Ruskin
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-10       Impact factor: 1.468

4.  Atherosclerotic plaque imaging by PET/CT; can inactive, active and mixed plaques be discerned?

Authors:  E E van der Wall; J D Schuijf; J W Jukema; J J Bax; A van der Laarse
Journal:  Int J Cardiovasc Imaging       Date:  2008-12-05       Impact factor: 2.357

5.  Tetralogy of Fallot: in good shape?

Authors:  Barbara J M Mulder; Ernst E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2008-12-16       Impact factor: 2.357

6.  Rabbit models: ideal for imaging purposes?

Authors:  A van der Laarse; E E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2008-12-16       Impact factor: 2.357

7.  Aortic and coronary atherosclerosis: a natural association?

Authors:  Ernst E van der Wall; Arnoud van der Laarse
Journal:  Int J Cardiovasc Imaging       Date:  2008-11-27       Impact factor: 2.357

8.  Monitoring plaque composition: is it worthwile?

Authors:  Arnoud van der Laarse; Ernst E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2008-11-27       Impact factor: 2.357

Review 9.  Atrial fibrillation and conduction system disease: the roles of catheter ablation and permanent pacing.

Authors:  Anand Thiyagarajah; Dennis H Lau; Prashanthan Sanders
Journal:  J Interv Card Electrophysiol       Date:  2018-08-03       Impact factor: 1.900

10.  Expanding indications for resynchronization therapy.

Authors:  Christophe Leclercq; Nathalie Behar; Philippe Mabo; Jean-Claude Daubert
Journal:  Curr Cardiol Rep       Date:  2012-10       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.